Jun 21 |
Nektar Therapeutics Likely To Drift And Wobble Ahead Of Key Phase II Data In 2025
|
Jun 12 |
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
|
Jun 5 |
Nektar Therapeutics' (NASDAQ:NKTR) investors will be pleased with their stellar 130% return over the last year
|
May 30 |
Nektar Management to Present at Upcoming Investor Conferences
|
May 30 |
Russell 3000: Inovio, Ocugen among healthcare additions; Assertio, Ginkgo Bioworks among deletions
|
May 28 |
Nektar files to sell 25M shares of common stock for holders
|
May 10 |
Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript
|
May 10 |
Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview
|
May 10 |
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
|
May 10 |
Q1 2024 Nektar Therapeutics Earnings Call
|